May 8, 2023 4:49pm

More frequently right than consequentially wrong

Earnings: CRISPR Therapeutics (CRSP)

Pre-Open Indications: 2 Hits and 1 Miss

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!  

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -55.69 points (-0.17%), the S&P closed UP +1.87 points (+0.05%) while the Nasdaq closed UP +21.50 points (+0.18%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies.

Indexes were mixed on Monday as investors await more cell and gene therapy sector earnings, the latest inflation report and a much-anticipated meeting between President Biden and House Speaker McCarthy over the debt ceiling this week.

 

52-week low:

  • Sangamo Therapeutics (SGMO) at $1.26

 

Monday (5/8) … RegMed Investors’ (RMi) pre-open: “I’d be watching and then selling after last Monday, Wednesday through Friday’s sector rally.” … https://www.regmedinvestors.com/articles/12948

 

Pre-Open Indications: 2 Hit < Ionis Pharmaceuticals (IONS -$1.02). CRISPR Therapeutics (CRSP +$0.17)>  and 1 Miss < Prime Medicine (PRME -$0.15),    

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Monday’s advance/decline line opened negative at 12 up/ 22 down and 1 flat, stayed negative with 14 up/ 19 down and 2 flats at the mid-day, ending with a negative close of 16/18 and 1 flat

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -0.81% and the XBI was down -0.45%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.21 points or -1.22% at 6.98.

 

Closing Down (10 of 18)

  • Alnylam Pharmaceuticals (ALNY -$2.09 after Friday’s +$6.66),
  • Ionis Pharmaceuticals (IONS -$1.02),
  • Intellia Therapeutics (NTLA -$0.71)
  • Regenxbio (RGNX -$0.43 after Friday’s -$1.03),
  • Beam Therapeutics (BEAM -$0.29 after Friday’s +$0.37),
  • Fate Therapeutics (FATE -$0.23 after Friday’s -$0.49),
  • BioLife Solutions (BLFS -$0.18 after Friday’s +$1.44),
  • Ultragenyx (RARE -$0.17 after Friday’s +$1.41
  • Editas Medicine (EDIT -$0.15 after Friday’s +$1.05),
  • Prime Medicine (PRME -$0.15 after Friday’s -$0.80),

Flat (1):

  • Biostage (OTCQB: BSTG)

Closing Up (10 of 16):

  • Chinook Therapeutics (KDNY +$0.85 after Friday’s +$0.71),
  • Sage Therapeutics (SAGE +$2.41 after Friday’s +$0.95),
  • Bellicum Pharmaceuticals (BLCM +$0.57),
  • uniQure NV (QURE +$0.29),
  • Voyager Therapeutics (VYGR +$0.25),
  • AxoGen (AXGN +$0.24 after Friday’s +$0.41),
  • Compass Therapeutics (CMPX +$0.17),
  • CRISPR Therapeutics (CRSP +$0.17 after Friday’s +$2.67),
  • MiMedx (MDXG +$0.08),
  • Solid Biosciences (SLDB +$0.06),

 

Q2/23 – May

  • Monday closed negative with 16 incliners, 18 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

As I had stated, “I wouldn’t be buying into this rally … I would be selling into this upside!”

Have you asked yourself, do you know why you own certain equity? What’s been communicated re a company’s status at any given time to shareholders other than quarterly reports or a once-upon-a-time press release!

There are clear winners — and losers — at the start of May.

The top three (3) performing:

·         Monday’s: Sage Therapeutics (SAGE), Chinook Therapeutics (KDNY) and Bellicum Pharmaceuticals (BLCM)

While The worst three (3):

·         Monday’s: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)

Percentage moves:

·         Upside: +0.30% to +% (xx)

·         Downside: -0.12% to -5.22% (x)

 

Earnings:

RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/12923  - adding 1 – CRISPR Therapeutics (CRSP)

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

De-Listing Update:

Avrobio (AVRO) – Monday closed up +0.01 to 0.71 after Friday closed up +$0.04 to $0.70 after Thursday closed down -$0.0093 to $0.655 after Wednesday closed up +$0.01 to $0.66 after Tuesday’s Tuesday closed down-$0.168 to $0.65 after Monday closed down -$0.01596 to $0.83 after CEO Geoff MacKay resigned; still under Nasdaq minimum rule of $1.00; after twenty-five (25) sessions

·         Will AVRO do a reverse split to up-end delisting to “SCREW” shareholders yet, AGAIN?

Verastem Oncology (VSTM) closed down yet again -$0.009 on Monday after Friday’s -$0.0171 after Thursday’s +$0.0061, Wednesday’s +$0.005 to $0.44, Tuesday’s -$0.0070 and Monday’s -$0.075; two hundred and one (201) sessions under the Nasdaq $1.00 minimum pricing

 

Biostage (OTCQB: BSTG) …

·         Monday close FLAT after Friday closed down +$0.01 with 215 share traded, Thursday closed down -$0.05 with 650 shares traded, Wednesday closed FLAT with 26 shares traded, Tuesday closed FLAT with 0 shares traded and last Monday closed FLAT with 0 shares traded <3-month average =1,590 shares>

·         Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         CEO Jerry, you should listen to Biostage’s critics to focus to the future, their insight could help you … over the sentiment speedbumps!

·         The past management team is and was disconnected with US investors and I-Banks; so, it behooves the new CEO to connect with a more solid story and reduce those who have brought the company to its toes!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.